Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-methylthioadenosine 5'-diphosphate (2Me-SADP) is a potent nucleotide analog that serves as an agonist for several P2Y purinergic receptors, most notably the P2Y1, P2Y12, and P2Y13 subtypes. It is widely utilized as a pharmacological research tool to investigate purinergic signaling pathways involved in platelet aggregation, neurotransmission, and vascular tone regulation. In experimental models of pulmonary hypertension, 2Me-SADP has been evaluated for its potential vasodilatory properties, although studies in rat arterial tissues have demonstrated relatively low maximal efficacy compared to other vasodilators like sildenafil or riociguat. It is primarily recognized as a high-affinity probe for characterizing the structure and function of ADP-binding purinoceptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-methylthioadenosine 5'-diphosphate.